Why the study?
Does a percutaneous cardiopulmonary bypass system (PCPS) rescue cardiogenic shock in a patient with pheochromocytoma?
Case Report (n=1)
No
Does a percutaneous cardiopulmonary bypass system (PCPS) rescue cardiogenic shock in a patient with pheochromocytoma?
Early use of a percutaneous cardiopulmonary bypass system can successfully rescue patients with reversible pheochromocytoma-induced cardiogenic shock.
Answers are grounded in this paper and cite their sources.
May support PCPS in pheochromocytoma shock; hypothesis-generating, needs prospective validation before practice change.
Pheochromocytoma is a rare cause of cardiogenic shock. Clinical management is directed at reducing the heart rate while maintaining blood pressure. However, medical treatment is often unsuccessful because of the high endogenous catecholamine level and low cardiac output. Percutaneous cardiopulmonary bypass system is a circulatory device that allows for safer use of heart-rate-reducing agents, which is advantageous when used early in the course of the cardiogenic shock induced by pheochromocytoma.
No takes yet. Share an insight, caveat, or question.
Park et al. (2009) conducted a case report in Pheochromocytoma-induced cardiogenic shock (n=1). Percutaneous cardiopulmonary bypass system (PCPS) was evaluated on Hemodynamic recovery and survival.
Synapse has enriched 10 related papers. Consider them for comparative context: